Aurobindo Pharma has reported consolidated net profit of Rs.91.81 crore during the third quarter ended December 2012 on account of lower foreign exchange loss, as against a net loss of Rs.28.54 crore in the corresponding period of last year. The company management declared interim dividend of 100 per cent.
Its foreign exchange loss declined to Rs.73.36 crore from Rs.144.50 crore in the last period. The EBDITA went up sharply to Rs.264.74 crore from Rs.196.39 crore with higher net sales. Its consolidated net sales increased by 22.8 per cent to Rs.1,552 crore from Rs.1,264 crore. The reported positive EPS of Rs.3.15 as against negative Rs.0.96 in the last period.
The company's formulation sales increased by 22.5 per cent to Rs.911.8 crore from Rs.744.3 crore and APIs sales by 21.7 per cent to Rs.660.2 crore from Rs.542.7 crore. Formulations sales constitute 58 per cent. It filed 11 new ANDAs during the quarter and its cumulative ANDA filings reached at 262. Similarly, it filed 21 dossier in Europe and cumulative filings reached at 1,337.
Its sales in USA improved by 58 per cent to Rs.513.4 crore from Rs.325.2 crore in the similar period of last year and that in Europe and RoW improved by 9.3 per cent to Rs.223.3 crore from Rs.204.3 crore. However, sales from ARV declined by 18.4 per cent to Rs.175.1 crore from Rs.214.6 crore.
N Govindarajan, managing director, said, “We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market. During the quarter, US FDA cleared Unit-4 (general liquid injectable) after their first inspection and Unit-12 (SSP oral & injectable) on re-inspection and started approving products from these facilities. These will pave the way for consolidating injectable formulations business.”
The net sales for the nine months period ended December 2012 increased by 25.2 per cent to Rs.4,230 crore from Rs.3,380 crore in the corresponding period of last year. Its EBDITA has taken a quantum jump of 35.8 per cent to Rs.663.58 crore from Rs.488.50 crore. It earned a net profit of Rs.185.25 crore as against a net loss of Rs.231.50 crore. The foreign exchange loss was at Rs.162.14 crore as compared to Rs.326.74 crore and its interest charges were higher by 47.6 per cent to Rs.99.73 crore from Rs.67.55 crore..